ESMO 2026 Preview: Oncology Innovations, Clinical Trials and AI
ESMO 2026 at a glance ESMO 2026 will spotlight emerging oncology trends as…
Merck–SciBrunch SPR2015: A $400M Preclinical Bet | Lucid Diligence Brief
This Lucid Diligence Brief examines Merck’s licensing deal for SciBrunch’s…
WCLC 2026 Preview: Emerging Lung Cancer Therapies and Competitive Trends
WCLC 2026 at a glance At IASLC-WCLC 2026, where will the next wave of…
Genprex Roche Diagnostics TROP2 Collaboration | Lucid Diligence Brief
Genprex and Roche Diagnostics begin TROP2 assay validation to support…
GSK Acquires Nuvalent to Expand Oncology Pipeline | Lucid Diligence Brief
GSK strengthens its oncology portfolio with Nuvalent acquisition, adding…
Oncology Today—June 2, 2026
This week’s Oncology update highlights precision-oncology momentum across…
ASCO 2026: Competitive Shifts in Oncology
ASCO at a glance ASCO 2026 highlights how oncology innovation is being tested…
ELCC 2026 Preview: Key Competitive Shifts in Lung Cancer
ELCC 2026 at a glance ELCC 2026 highlights key lung cancer treatment trends,…
Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and Tedopi
Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and…
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal Professional…
Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+ NSCLC
Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+…
Oncology Today—November 17, 2025
This week in oncology, we spotlight the most relevant updates, approvals, and…